Andera leads Crescendo’s $70M series B

Crescendo Biologics Ltd. (Cambridge, U.K.) raised $70 million in a series B round led by new investor Andera Partners (formerly Edmond de Rothschild Investment Partners). Fellow new investor Quan Capital joined existing investors Sofinnova Partners, IP Group, EMBL and Takeda Ventures.

Crescendo develops Humabodies -- small antigen-binding proteins composed of human immunoglobulin heavy chain variable region (Ighv) fragments generated in mice (see BioCentury Innovations, April 6, 2017). ...